Nykode Therapeutics ASA (NYKD) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.057x

Based on the latest financial reports, Nykode Therapeutics ASA (NYKD) has a cash flow conversion efficiency ratio of -0.057x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Nkr-59.64 Million ≈ $-6.28 Million USD) by net assets (Nkr1.05 Billion ≈ $110.32 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Nykode Therapeutics ASA balance sheet independence to measure how much of total assets are equity-financed.

Nykode Therapeutics ASA - Cash Flow Conversion Efficiency Trend (2016–2024)

This chart illustrates how Nykode Therapeutics ASA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Nykode Therapeutics ASA cash flow quality index to evaluate the quality of earnings relative to operating cash generation.

Nykode Therapeutics ASA Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Nykode Therapeutics ASA ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Clarus Corp NASDAQ:CLAR	-0.021x
Zevia Pbc NYSE:ZVIA	0.003x
Caisse Régionale du Crédit Agricole Alpes Provence PA:CRAP	0.041x
Affluent Medical SAS PA:AFME	-0.319x
Talga Group Ltd AU:TLG	-0.155x
Global Mediacom Tbk JK:BMTR	0.013x
Tesoro Gold Ltd AU:TSO	-0.013x
GAMSUNG Corporation Co. Ltd KQ:036620	-0.037x

Annual Cash Flow Conversion Efficiency for Nykode Therapeutics ASA (2016–2024)

The table below shows the annual cash flow conversion efficiency of Nykode Therapeutics ASA from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see Nykode Therapeutics ASA (NYKD) total market value.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	Nkr136.21 Million ≈ $14.33 Million	Nkr-51.22 Million ≈ $-5.39 Million	-0.376x	+33.35%
2023-12-31	Nkr171.26 Million ≈ $18.02 Million	Nkr-96.62 Million ≈ $-10.17 Million	-0.564x	-328.11%
2022-12-31	Nkr157.02 Million ≈ $16.52 Million	Nkr-20.69 Million ≈ $-2.18 Million	-0.132x	-2314.20%
2021-12-31	Nkr194.06 Million ≈ $20.42 Million	Nkr1.16 Million ≈ $121.54K	0.006x	-99.41%
2020-12-31	Nkr178.85 Million ≈ $18.82 Million	Nkr180.27 Million ≈ $18.97 Million	1.008x	+365.51%
2019-12-31	Nkr242.56 Million ≈ $25.52 Million	Nkr-92.08 Million ≈ $-9.69 Million	-0.380x	+15.31%
2018-12-31	Nkr140.07 Million ≈ $14.74 Million	Nkr-62.78 Million ≈ $-6.61 Million	-0.448x	-45.30%
2017-12-31	Nkr203.53 Million ≈ $21.42 Million	Nkr-62.78 Million ≈ $-6.61 Million	-0.308x	-347.33%
2016-12-31	Nkr23.19 Million ≈ $2.44 Million	Nkr-1.60 Million ≈ $-168.25K	-0.069x	--

About Nykode Therapeutics ASA

OL:NYKD Norway Biotechnology

Market Cap

$110.30 Million

Nkr1.05 Billion NOK

Market Cap Rank

#18824 Global

#166 in Norway

Share Price

Nkr3.21

Change (1 day)

-5.03%

52-Week Range

Nkr1.47 - Nkr3.88

All Time High

Nkr91.25